Suppliers and packagers for ILUVIEN

ILUVIEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923	NDA	ANI Pharmaceuticals, Inc.	68611-190-02	1 TRAY in 1 CARTON (68611-190-02) / 1 APPLICATOR in 1 TRAY / 1 IMPLANT in 1 APPLICATOR	2014-10-15

Suppliers for the Pharmaceutical Drug: ILUVIEN

Last updated: July 29, 2025

Introduction

ILUVIEN (fluocinolone acetonide intravitreal implant) is a sustained-release corticosteroid approved for the treatment of diabetic macular edema (DME) in adult patients, particularly those insufficiently responsive to prior therapies. Manufactured by Alimera Sciences, ILUVIEN is embedded within a biodegradable implant designed for intraocular delivery, offering prolonged pharmacological activity over 36 months. As a specialized ophthalmic device, ILUVIEN’s supply chain involves multiple stakeholders encompassing manufacturing, distribution, and authorized pharmacy channels. This article provides an in-depth analysis of primary suppliers, manufacturing entities, and the global distribution framework that supports ILUVIEN availability within healthcare markets.

Manufacturing and Origin of ILUVIEN

ILUVIEN’s manufacturing process is highly regulated, adhering to stringent Good Manufacturing Practice (GMP) standards set by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The drug's active pharmaceutical ingredient, fluorescein acetonide, is encapsulated within a biodegradable polymer matrix to ensure controlled release.

Alimera Sciences, headquartered in Alpharetta, Georgia, primarily holds the rights to manufacture and distribute ILUVIEN globally. The company oversees the entire manufacturing process, maintaining specialized production facilities compliant with international standards. The manufacturing site designated for ILUVIEN production has not been publicly disclosed; however, it is likely to be certified by relevant authorities, including the FDA or EMA, depending on regional distribution.

Authorized Distributors and Supply Partners

Due to the specialized nature of ILUVIEN, Alimera Sciences employs a network of authorized distributors and partners to facilitate regional supply. The distribution channels are typically region-specific, with partnerships tailored to regulatory environments, market demand, and healthcare infrastructure.

1. Alimera Sciences Direct Distribution Model

In some markets, Alimera Sciences handles direct distribution, leveraging its global sales team and logistics infrastructure. This approach ensures tighter control over product quality, supply consistency, and regulatory compliance. For example, in the United States—where ILUVIEN received FDA approval in 2015—the company distributes directly to specialized ophthalmic centers and healthcare providers.

2. Regional and National Distributors

In Europe and other markets, Alimera collaborates with regional distributors licensed to sell ILUVIEN within specific territories. These distributors are responsible for warehousing, regulatory compliance, and logistics, often operating in partnership with local healthcare authorities.

In Europe, for instance, distributors such as Mediwin and Wilco serve as key partners. These entities are responsible for ensuring supply chain integrity, managing cold chain logistics if necessary, and adhering to country-specific regulatory and reimbursement frameworks.

3. Authorized Pharmacies and Healthcare Providers

Final delivery of ILUVIEN occurs through healthcare providers—specifically ophthalmologists and retina specialists—who administer the implant in clinical settings. In several jurisdictions, hospitals or clinics procure ILUVIEN through authorized distributors or directly via prescription channels.

Global Manufacturing and Supply Chains

Given the geographic complexities, ILUVIEN’s supply chain includes multiple phases:

• Raw Material Sourcing: Critical raw materials, including fluocinolone acetonide and biodegradable polymers, are sourced globally from certified suppliers with appropriate quality standards. These raw materials are typically procured from specialized chemical manufacturers with GMP certification.

• Manufacturing Process: The manufacturing process involves mixing the active drug with biodegradable polymers, sterilization, filling into preloaded ocular implants, and rigorous quality testing. The process is conducted in controlled environment facilities adjacent to or within Alimera’s manufacturing sites.

• Packaging and Storage: Post-manufacture, ILUVIEN implants are packaged in sterile, sealed units designed to preserve integrity during transit. Storage conditions are maintained strictly within recommended temperature ranges, generally between 2°C to 8°C, with validated cold chain logistics.

• Distribution Logistics: The supply chain employs both air and ground logistics, depending on regional needs. Cold chain logistics are critical in maintaining product stability, especially during international transit. Alimera partners with logistics providers specializing in pharmaceutical supply, such as DHL or FedEx, with experience in handling sensitive biological products.

Regulatory and Compliance Considerations

Suppliers and distributors must adhere to regulatory requirements, including:

• GMP for manufacturing facilities

• Excellent Distribution Practice (GDP) for logistics

• Regional regulatory approvals (e.g., FDA, EMA, PMDA in Japan)

• Serialization and track-and-trace measures to prevent counterfeit infiltration

• Pharmacovigilance systems to monitor post-market drug safety

Maintaining compliance across individual regions ensures continuity of supply and mitigates risk factors associated with regulatory non-conformance.

Market-Specific Supplier Details

Region	Key Suppliers/Distributors	Regulatory Status
United States	Alimera Sciences (direct distribution)	FDA-approved, distributed through ophthalmic clinics
European Union	Local authorized distributors (e.g., Mediwin)	EMA approval, distributed via licensed healthcare providers
Asia-Pacific	Regional partners, local importers	Varies per country; approvals pending/in place
Latin America	Regional distributors, authorized pharmacies	Local regulatory approvals required

Supply Chain Challenges and Risk Mitigation

Despite robust manufacturing, supply chains face potential disruptions:

• Regulatory delays: Obtaining or renewing approvals may impact supply continuity.

• Raw material shortages: Limited suppliers for critical raw materials increase vulnerability.

• Manufacturing capacity constraints: Limited production sites can create bottlenecks.

• Logistical disruptions: Global events (e.g., pandemics, geopolitical issues) impact cold chain logistics.

Alimera maintains contingency plans, including diversified sourcing, inventory management, and strategic partnerships, to minimize disruptions.

Conclusion

ILUVIEN’s supply chain is a finely tuned operation involving manufacturing primarily by Alimera Sciences, complemented by a network of authorized regional distributors and healthcare providers. The complexity of intraocular implant manufacturing, regulatory compliance, and temperature-sensitive logistics underscores the importance of specialized suppliers and rigorous supply chain management. Continued global expansion will likely involve partnerships with regional distributors, highlighting the critical role of local supply infrastructure in ensuring patient access to this advanced therapeutic.

---

Key Takeaways

• Manufacturing Control: Alimera Sciences centrally manufactures ILUVIEN in GMP-compliant facilities, ensuring product quality and regulatory adherence.

• Regional Distribution Networks: The drug relies on a network of local authorized distributors and licensed pharmacies tailored to regional regulatory environments.

• Logistics & Cold Chain: Maintaining cold chain integrity is vital; leading logistics providers facilitate international shipping within strict temperature controls.

• Market Adaptation: Customizable regional supply strategies accommodate diverse regulatory and healthcare system requirements.

• Supply Chain Resilience: Diversified sourcing, inventory buffer strategies, and robust compliance practices mitigate risks to ongoing supply.

---

FAQs

1. Who are the primary manufacturers of ILUVIEN?
Alimera Sciences is the exclusive manufacturer of ILUVIEN, overseeing production in GMP-compliant facilities tailored to regional regulatory standards.

2. How is ILUVIEN distributed globally?
Distribution is managed through a mix of direct company-controlled channels in some markets (e.g., the U.S.) and authorized regional distributors in others, such as Europe and Asia.

3. What logistical considerations are critical for ILUVIEN supply?
Due to its intraocular implant form, ILUVIEN's supply chain demands strict cold chain management—temperature-controlled logistics to preserve product integrity during transit.

4. Are there any third-party suppliers involved in raw materials for ILUVIEN?
Yes, raw materials like fluocinolone acetonide and biodegradable polymers are sourced from specialized chemical and pharmaceutical suppliers with GMP certification, though specifics are proprietary.

5. What risks could disrupt the supply of ILUVIEN?
Potential risks include regulatory delays, raw material shortages, manufacturing capacity constraints, and logistical disruptions such as transportation or geopolitical issues.

---

Sources

1. Alimera Sciences Press Releases and Website: https://www.alimerasciences.com
2. U.S. Food and Drug Administration (FDA) Approvals and Guidelines
3. European Medicines Agency (EMA) Product Information
4. Industry reports on ophthalmic drug manufacturing and distribution
5. Market analysis on specialized pharmaceutical supply chains